-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Downgrades Day One Biopharmaceutical to Neutral, Lowers Price Target to $21.5

Benzinga·03/11/2026 14:17:02
Listen to the news
JP Morgan analyst Anupam Rama downgrades Day One Biopharmaceutical (NASDAQ:DAWN) from Overweight to Neutral and lowers the price target from $27 to $21.5.